Evidence map›Paper›PMID 21795333›Full record

ArticleJournal of virology2011

Epstein-Barr virus latent membrane protein 1 (LMP1) C-terminal-activating region 3 contributes to LMP1-mediated cellular migration via its interaction with Ubc9.

Gretchen L Bentz, Christopher B Whitehurst, Joseph S Pagano

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. SUMO: a novel target for anti-coronavirus therapy.Pathogens and global health · 2021
    Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Gretchen L BentzDepartment of Medicine and Microbiology, The University of North Carolina, Chapel Hill, NC, USA.
Christopher B Whitehurst
Joseph S Pagano
University of North Carolina at Chapel Hill · USUNC Lineberger Comprehensive Cancer Center

Funding

Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
New EBV Therapies for treating malignanciesR01HL064851 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PAGANO, JOSEPH S · 2000 to 2009
$2.5M
The Induction of Interferon Regulatory Factor 7 Sumoylation by EBV LMP1F32CA142132 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BENTZ, GRETCHEN L · 2010 to 2010
$52k
NCI NIH HHS CA09156NCI NIH HHS CA142132NCI NIH HHS F32 CA142132NCI NIH HHS T32 CA009156NHLBI NIH HHS HL-64851NHLBI NIH HHS R01 HL064851
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1), the principal viral oncoprotein and a member of the tumor necrosis factor receptor superfamily, is a constitutively active membrane signaling protein that regulates multiple signal transduction pathways via its C-terminal-activating region 1 (CTAR1) and CTAR2, and also the less-studied CTAR3. Because protein sumoylation among other posttranslational modifications may regulate many signaling pathways induced by LMP1, we investigated whether during EBV latency LMP1 regulates sumoylation processes that control cellular activation and cellular responses. By immunoprecipitation experiments, we show that LMP1 interacts with Ubc9, the single reported SUMO-conjugating enzyme. Requirements for LMP1-Ubc9 interactions include enzymatically active Ubc9: expression of inactive Ubc9 (Ubc9 C93S) inhibited the LMP1-Ubc9 interaction. LMP1 CTAR3, but not CTAR1 and CTAR2, participated in the LMP1-Ubc9 interaction, and amino acid sequences found in CTAR3, including the JAK-interacting motif, contributed to this interaction. Furthermore, LMP1 expression coincided with increased sumoylation of cellular proteins, and disruption of the Ubc9-LMP1 CTAR3 interaction almost completely abrogated LMP1-induced protein sumoylation, suggesting that this interaction promotes the sumoylation of downstream targets. Additional consequences of the disruption of the LMP1 CTAR3-Ubc9 interaction revealed effects on cellular migration, a hallmark of oncogenesis. Together, these data demonstrate that LMP1 CTAR3 does in fact function in intracellular signaling and leads to biological effects. We propose that LMP1, by interaction with Ubc9, modulates sumoylation processes, which regulate signal transduction pathways that affect phenotypic changes associated with oncogenesis.

Indexed as

Host-Pathogen InteractionsVirus LatencyAmino Acid MotifsBinding SitesCell LineHerpesvirus 4, HumanHumansImmunoprecipitationProtein BindingProtein Interaction MappingUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9Viral Matrix ProteinsEBV-associated membrane antigen, Epstein-Barr virusUbiquitin-Conjugating EnzymesUbiquitin-Conjugating Enzyme UBC9Viral Matrix Proteins

Identifiers

PMID21795333
PMCPMC3196420
OpenAlexW2133208695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.